We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Soft Trading Activities to Hurt Citigroup's (C) Q1 Earnings
Read MoreHide Full Article
Citigroup’s (C - Free Report) first-quarter 2019 earnings, slated on Apr 15, before the opening bell, are likely to be affected by the challenging trading environment.
Concerns over global economic slowdown, trade war fears and the government shutdown likely resulted in a sluggish environment for trading activities. Further, during the Investors Day conference in March, CFO Mark Mason projected a disappointing trading scenario.
The company expects markets revenues to fall in the "high single digits" percentage against an unusually strong quarter a year ago. "We've started to see markets stabilize and trade higher, but we haven't yet seen a full recovery from a year ago," Mason said.
Other Factors to Influence Q1 Results
Consumer Banking Revenues to Witness Growth: In consumer banking, the company expects to see continued strength in Mexico and Asia, lending support to revenues. Also, the net interest revenue percentage should improve both sequentially and year over year. Further, U.S. Branded Cards business saw a pickup in late-2018, which is likely to have continued in the first quarter.
Further, for 2019, management pointed other revenue tailwinds, including the absence of the FDIC surcharge, and a smaller expected drag from the winding down of legacy assets in Corp/Other. The to-be-reported quarter results should reflect these benefits.
Muted Investment Banking Fees: Slowdown in Investment banking performance was witnessed in the first quarter on the Fed’s dovish monetary policy, government shutdown and fears of economic slowdown. Thus, equity underwriting and debt origination fees are projected to decline slightly. Moreover, global M&A deal value and volume witnessed a decline owing to increase in borrowing costs and several geopolitical concerns, thereby hurting advisory fees.
However, Citigroup expects investment banking business to be on an upswing. Investment Banking revenues are estimated to rise in the first quarter on a year-over-year basis as M&As and debt issuance activities gained strength.
Lesser Scope of Cost Containment: As majority of unnecessary expenses have already been cut by the bank, expense reduction might not be a major support. Nonetheless, some legal settlements during the quarter might have affected Citigroup’s earnings to some extent.
Rise in Net Interest Income: Flattening and even inversion of the yield curve during the first quarter might negatively impact banks’ net interest margin, while December 2018 rate hike may lend some support. Also, per the Fed ’s latest data, loans are predicted to improve on a sequential basis. Particularly, weakness in revolving home equity loans is expected to be offset by significant growth in commercial and industrial and consumer loans.
Management expects net interest revenue percentage to improve sequentially during the first quarter.
Here is what our quantitative model predicts:
According to our model, chances of Citigroup beating the Zacks Consensus Estimate in the first quarter are low. This is because it does not have the right combination of the two key ingredients — a positive Earnings ESPand Zacks Rank #3 (Hold) or higher — for increasing the odds of an earnings beat.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: The Earnings ESP for Citigroup is +0.42%.
Zacks Rank: Citigroup currently carries a Zacks Rank #4 (Sell), which decreases the predictive power of ESP.
The Zacks Consensus Estimate for earnings of $1.78 reflects a 6% year-over-year rise. However, the consensus estimate for sales of $18.7 billion indicates nearly 1% decline.
Here are some stocks you may want to consider, as according to our model these have the right combination of elements to post an earnings beat this quarter.
The Bank of New York Mellon Corporation (BK - Free Report) is scheduled to release results on Apr 17. The company, which carries a Zacks Rank of 3, has an Earnings ESP of +0.63%.
The Earnings ESP for First Republic Bank is +1.27% and it carries a Zacks Rank of 3. The company is scheduled to report quarterly numbers on Apr 12.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Soft Trading Activities to Hurt Citigroup's (C) Q1 Earnings
Citigroup’s (C - Free Report) first-quarter 2019 earnings, slated on Apr 15, before the opening bell, are likely to be affected by the challenging trading environment.
Concerns over global economic slowdown, trade war fears and the government shutdown likely resulted in a sluggish environment for trading activities. Further, during the Investors Day conference in March, CFO Mark Mason projected a disappointing trading scenario.
The company expects markets revenues to fall in the "high single digits" percentage against an unusually strong quarter a year ago. "We've started to see markets stabilize and trade higher, but we haven't yet seen a full recovery from a year ago," Mason said.
Other Factors to Influence Q1 Results
Consumer Banking Revenues to Witness Growth: In consumer banking, the company expects to see continued strength in Mexico and Asia, lending support to revenues. Also, the net interest revenue percentage should improve both sequentially and year over year. Further, U.S. Branded Cards business saw a pickup in late-2018, which is likely to have continued in the first quarter.
Further, for 2019, management pointed other revenue tailwinds, including the absence of the FDIC surcharge, and a smaller expected drag from the winding down of legacy assets in Corp/Other. The to-be-reported quarter results should reflect these benefits.
Muted Investment Banking Fees: Slowdown in Investment banking performance was witnessed in the first quarter on the Fed’s dovish monetary policy, government shutdown and fears of economic slowdown. Thus, equity underwriting and debt origination fees are projected to decline slightly. Moreover, global M&A deal value and volume witnessed a decline owing to increase in borrowing costs and several geopolitical concerns, thereby hurting advisory fees.
However, Citigroup expects investment banking business to be on an upswing. Investment Banking revenues are estimated to rise in the first quarter on a year-over-year basis as M&As and debt issuance activities gained strength.
Lesser Scope of Cost Containment: As majority of unnecessary expenses have already been cut by the bank, expense reduction might not be a major support. Nonetheless, some legal settlements during the quarter might have affected Citigroup’s earnings to some extent.
Rise in Net Interest Income: Flattening and even inversion of the yield curve during the first quarter might negatively impact banks’ net interest margin, while December 2018 rate hike may lend some support. Also, per the Fed ’s latest data, loans are predicted to improve on a sequential basis. Particularly, weakness in revolving home equity loans is expected to be offset by significant growth in commercial and industrial and consumer loans.
Management expects net interest revenue percentage to improve sequentially during the first quarter.
Here is what our quantitative model predicts:
According to our model, chances of Citigroup beating the Zacks Consensus Estimate in the first quarter are low. This is because it does not have the right combination of the two key ingredients — a positive Earnings ESPand Zacks Rank #3 (Hold) or higher — for increasing the odds of an earnings beat.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: The Earnings ESP for Citigroup is +0.42%.
Zacks Rank: Citigroup currently carries a Zacks Rank #4 (Sell), which decreases the predictive power of ESP.
The Zacks Consensus Estimate for earnings of $1.78 reflects a 6% year-over-year rise. However, the consensus estimate for sales of $18.7 billion indicates nearly 1% decline.
Citigroup Inc. Price and EPS Surprise
Citigroup Inc. Price and EPS Surprise | Citigroup Inc. Quote
Stocks That Warrant a Look
Here are some stocks you may want to consider, as according to our model these have the right combination of elements to post an earnings beat this quarter.
Comerica Incorporated (CMA - Free Report) is scheduled to release results on Apr 16. It has an Earnings ESP of +0.52% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Bank of New York Mellon Corporation (BK - Free Report) is scheduled to release results on Apr 17. The company, which carries a Zacks Rank of 3, has an Earnings ESP of +0.63%.
The Earnings ESP for First Republic Bank is +1.27% and it carries a Zacks Rank of 3. The company is scheduled to report quarterly numbers on Apr 12.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>